Form 4: REGENXBIO Director Allan Fox Reports Stock Transactions

Director Allan M. Fox of REGENXBIO Inc. reported transactions involving common stock and stock options, including the acquisition of shares underlying a restricted stock unit award.

Summary

• Director Allan M. Fox of REGENXBIO Inc. filed a Form 4 reporting transactions related to his beneficial ownership of the company's common stock.
• The filing details the acquisition of 9,807 shares of common stock underlying a restricted stock unit (RSU) award, with 100% vesting scheduled for May 29, 2027.
• Additionally, Fox acquired 46,600 stock options with an exercise price of $7.01, which are also set to vest on May 29, 2027.
• The report also lists indirect beneficial ownership of significant amounts of common stock through various trusts and LLCs, including AMF Family Gift Trust LLC, AMF Gift Trust LLC, HBF Gift Trust LLC, and Quaker Gray LLC.
• Fox disclaims beneficial ownership of shares held indirectly except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions and compensation structures rather than significant financial performance or strategic shifts.

Positives

• Director Allan M. Fox has acquired shares through an RSU award, indicating continued alignment with the company's performance.
• The acquisition of stock options suggests a belief in the future appreciation of REGENXBIO's stock price.
• The reporting of these transactions demonstrates transparency and adherence to SEC disclosure requirements.

Negatives

• The filing does not contain information on the financial performance of REGENXBIO Inc., focusing solely on director transactions.
• Details regarding the specific reasons for the RSU award or option grant are not provided.

Risks

• The vesting of RSUs and stock options is contingent upon the continuous service of the recipient to the Issuer, implying a risk of forfeiture if service is terminated before the vesting date.
• Indirect beneficial ownership through various entities may introduce complexities in understanding direct control and decision-making.

Future Outlook

The future outlook for the reported transactions is tied to the vesting schedule of the RSUs and stock options, which are dependent on the continuous service of Allan M. Fox to REGENXBIO Inc. and are set to vest on May 29, 2027.

Management Comments

• The reporting person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insiders of publicly traded companies, reflecting typical compensation and ownership structures within the biotechnology sector. The structure of RSU and option grants is common for incentivizing key personnel.

Stakeholder Impact

• Shareholders: The transactions reflect standard compensation practices for directors and may indicate management's confidence in future stock performance, but do not directly impact current share value.
• Employees: The RSU and option grants are part of the overall compensation strategy for key personnel.
• Management: The transactions are part of Allan M. Fox's compensation and ownership stake in the company.

Next Steps

• Continuous service of Allan M. Fox to REGENXBIO Inc. until May 29, 2027, for full vesting of RSUs and stock options.
• Potential exercise of stock options after vesting on May 29, 2027.

Key Dates

Keywords

REGENXBIO, RGNX, Form 4, SEC Filing, Director Transactions, Stock Options, RSU, Beneficial Ownership, Allan M. Fox